Adding yet another twist to the ongoing proxy fight at Amylin Pharmaceuticals, co-founder Howard Greene last week sided with dissident investors Carl Icahn and Eastbourne Capital Management in encouraging shareholders to vote for new leadership on the board...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99